Otsuka
Top Ten most popular articles on Pharmafile.com this week!
June 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, GSK, J&J, JJ, Otsuka, Pfizer, Purdue, Sanofi, Vertex, pharma
Pfizer supressed research showing their arthritis drug Enbrel reduced the risk of Alzheimer’s. This was the big revelation this week! …
Otsuka to take over Astellas’ Cefixime business
June 7, 2019Medical Communications APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma
Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime. The agreement gives Otsuka the right to sell Cefixime and …
Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect
February 15, 2019Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health
Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …
Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3
August 1, 2018Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia
It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …
Otsuka snaps up Visterra in $430 million deal
July 12, 2018Research and Development, Sales and Marketing Otsuka, Visterra, acquisition, pharma
Otsuka Pharmaceutical has announced it has reached a definitive, board-approved agreement with Visterra to acquire the latter company in an …
Lundbeck, Otsuka’s trial Alzheimer’s disease drug gets US FDA fast track designation
July 8, 2016Medical Communications, Research and Development Alzheimer's disease, Lundbeck, Otsuka, US FDA, drug development, drug trial, fast track designation
H. Lundbeck A/S (CPH: LUN) and Otsuka Pharmaceutical said the US Food and Drug Administration (FDA) have granted Fast Track …
Lundbeck gets go-ahead for US and EU licence expansions
February 4, 2016Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine
Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
SMC approves first ever treatment for genetic kidney disease
January 12, 2016Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
US FDA accepts first digital medicine application
September 11, 2015Medical Communications FDA, NDA, Otsuka, digital, digital medicine, proteus
The FDA has accepted the first New Drug Application for a digital medicine: Otsuka and Proteus Digital Health’s collaboration of …
FDA approves Lundbeck and Otsuka’s Rexulti for depression
July 14, 2015Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia
Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …
Otsuka, ViiV and AstraZeneca named in ABPI code complaints
May 26, 2015Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Otsuka, PMCPA, ViiV
A ‘senior male employee’ of Otsuka Pharmaceuticals “potentially brought the industry into disrepute” by plying a female healthcare professional with …
Three drugs put forward for EMA authorisation
March 2, 2015Research and Development, Sales and Marketing Amgen, EMA, FDA, Novartis, Otsuka, jinarc, ristempa, zykadia
Novartis’ lung cancer drug Zykadia has been recommended for EU approval in patients previously treated with Pfizer’s Xalkori – the …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Pharma to lose $69 billion in five years as patents expire
December 12, 2014Sales and Marketing AstraZeneca, GlobalData, Japanese firm Otsuka, Otsuka, lilly, pharma
Pharma companies are set to lose around $65 billion by 2019 due to drug patent expiries according to research firm …
Latest content
FibroFind appoints Lee Borthwick as CEO
